Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542200 · ClinicalTrials.gov registry record
Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 40,132
- Enrollment target
NCT04542200: Completed study, sponsored by Northwell Health.
NCT04542200 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 40,132 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542200 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 40,132 participants
- Enrollment target
Study Summary
The goal, with this study, is to leverage Northwell Health System's diverse workforce and robust testing structures, to contribute data-driven, evidence-based strategies to better understand the sustained prevalence of antibodies and how conferred immunity may be modified by environmental factors. The objective is to investigate the COVID-19/SARS-CoV-2 disease prevalence and trajectory over time, by conducting follow-up antibody testing on employees who consented to participate in research during the initial workforce offering. From 70,812 employees contacted, 46,117 were tested and received initial results. Of those participants, approximately, 32,000 agreed to be re-contacted, and 34,000 consented to research. The investigators plan to conduct an additional five rounds of testing that would sample individuals over a two-year period. This study is significant because it leverages Northwell Health's advanced laboratory systems to conduct serosurveillance of antibodies to COVID-19/SARS-CoV-2 across a large and diverse workforce, while taking into account the contextual environmental and occupational exposures that may modify continued immunity to the virus. Northwell Health's employee health services (EHS) is poised to act quickly to adapt policies and practices, where needed, to protect the workforce. The study is also innovative because it will be linking work environment and community measures with COVID-19 seropositive prevalence patterns over time, to build a better understanding of the disease and its controls at the population level. The expected outcomes include serial serology results as a measure of full or partial short-term (6 months) and long-term (2 year) immunity to re-infection and recognition of local environmental factors (e.g., building ventilation rates, zip code, air quality indicators) that could modify this immunity and assist with protecting the workforce and surrounding community. These results could inform national and global policies.
Primary Outcome
serology testing
Interventions
- BIOLOGICAL Antibody testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,132 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2022-12-31 |
What the finished NCT04542200 record still lists
NCT04542200 is an observational study that tracks outcomes without assigning an intervention. Its 40,132 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Antibody testing is the first listed.
NCT04542200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04542200 about?
NCT04542200 is a clinical study titled "Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment". The goal, with this study, is to leverage Northwell Health System's diverse workforce and robust testing structures, to contribute data-driven, evidence-based strategies to better understand the sustained prevalence of antibodies and how conferred immunity may be modified by environmental factors. T...
What is the current status of trial NCT04542200?
This trial is currently completed. The enrollment target is 40,132 participants. The study started on 2021-01-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04542200?
The interventions under investigation include: Antibody testing (BIOLOGICAL).
Who is sponsoring clinical trial NCT04542200?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI